Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.
作者信息
Moayyedi Paul, Yuan Yuhong, Leontiadis Grigorios
出版信息
Can J Gastroenterol. 2013 Oct;27(10):593-5. doi: 10.1155/2013/321379.
Abstract
摘要
相似文献
1
Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.加拿大胃肠病学协会立场声明：髋部骨折与质子泵抑制剂治疗——2013年更新版
Can J Gastroenterol. 2013 Oct;27(10):593-5. doi: 10.1155/2013/321379.
2
Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.质子泵抑制剂的使用与卒中患者骨质疏松症和骨折风险：一项基于人群的队列研究。
Osteoporos Int. 2018 Jan;29(1):153-162. doi: 10.1007/s00198-017-4262-2. Epub 2017 Oct 14.
3
Use of proton pump inhibitors and risk of osteoporosis-related fractures.质子泵抑制剂的使用与骨质疏松相关骨折的风险
CMAJ. 2008 Aug 12;179(4):319-26. doi: 10.1503/cmaj.071330.
4
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.质子泵抑制剂的使用与骨质疏松或骨密度加速丢失无关。
Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.
5
Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.髋部骨折与质子泵抑制剂治疗：权衡利弊证据
Am J Gastroenterol. 2008 Oct;103(10):2428-31. doi: 10.1111/j.1572-0241.2008.02031.x.
6
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.用于治疗炎症性肠病的后续进入生物制剂概述及加拿大胃肠病学协会关于后续进入生物制剂的立场声明。
Can J Gastroenterol. 2013 Oct;27(10):567-71. doi: 10.1155/2013/327120.
7
Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.质子泵抑制剂与髋部骨折风险：观察性研究的荟萃分析。
Osteoporos Int. 2019 Jan;30(1):103-114. doi: 10.1007/s00198-018-4788-y. Epub 2018 Dec 12.
8
Proton pump inhibitors and fractures? Beware long-term use.质子泵抑制剂与骨折？谨防长期使用。
Prescrire Int. 2009 Oct;18(103):216.
9
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).质子泵抑制剂使用与骨密度纵向变化的关系：来自加拿大多中心骨质疏松研究（CaMos）的一项基于人群的研究[更正]。
Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10.
10
The effect of proton pump-inhibiting drugs on mineral metabolism.质子泵抑制药物对矿物质代谢的影响。
Am J Gastroenterol. 2009 Mar;104 Suppl 2:S2-4. doi: 10.1038/ajg.2009.44.
引用本文的文献
1
ACG and CAG Clinical Guideline: Management of Dyspepsia.ACG 和 CAG 临床指南：消化不良的管理。
Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154. Epub 2017 Jun 20.
2
Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.荷兰老年低剂量乙酰水杨酸使用者使用质子泵抑制剂进行胃保护的成本效益
Drugs Aging. 2017 May;34(5):375-386. doi: 10.1007/s40266-017-0447-9.
3
Proton pump inhibitors and risk of bone fractures.质子泵抑制剂与骨折风险
Curr Treat Options Gastroenterol. 2014 Dec;12(4):414-23. doi: 10.1007/s11938-014-0030-y.
4
A benefit-risk assessment of the use of proton pump inhibitors in the elderly.质子泵抑制剂在老年人中的使用的获益-风险评估。
Drugs Aging. 2014 Apr;31(4):263-82. doi: 10.1007/s40266-014-0166-4.
本文引用的文献
1
Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.质子泵抑制剂的使用与地中海地区髋部脆性骨折风险的关系。
Bone. 2013 Feb;52(2):557-61. doi: 10.1016/j.bone.2012.09.028. Epub 2012 Sep 27.
2
Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure.住院老年心力衰竭患者胸椎骨折的患病率。
Eur J Endocrinol. 2012 Dec;167(6):865-72. doi: 10.1530/EJE-12-0566. Epub 2012 Sep 11.
3
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.质子泵抑制剂对骨折风险的影响：来自加拿大多中心骨质疏松症研究的报告。
Osteoporos Int. 2013 Apr;24(4):1161-8. doi: 10.1007/s00198-012-2112-9. Epub 2012 Aug 14.
4
Hip fracture and risk of acute myocardial infarction: a nationwide study.髋部骨折与急性心肌梗死风险：一项全国性研究。
J Bone Miner Res. 2013 Feb;28(2):404-11. doi: 10.1002/jbmr.1714.
5
Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients.质子泵抑制剂会增加丙型肝炎患者骨折的发生率。
Dig Dis Sci. 2012 Sep;57(9):2416-22. doi: 10.1007/s10620-012-2185-5. Epub 2012 May 22.
6
Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.抗逆转录病毒治疗对 HIV 患者骨折风险的总体获益：一项在医疗保险人群中进行的巢式病例对照分析。
AIDS. 2012 Jun 1;26(9):1073-82. doi: 10.1097/QAD.0b013e328351997f.
7
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.质子泵抑制剂的使用与髋部骨折风险与饮食和生活方式因素的关系：一项前瞻性队列研究。
BMJ. 2012 Jan 30;344:e372. doi: 10.1136/bmj.e372.
8
Factors associated with the initiation of proton pump inhibitors in corticosteroid users.与皮质类固醇使用者启动质子泵抑制剂相关的因素。
Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):366-74. doi: 10.1002/pds.2350. Epub 2012 Jan 25.
9
Levothyroxine dose and risk of fractures in older adults: nested case-control study.左甲状腺素剂量与老年人骨折风险：巢式病例对照研究。
BMJ. 2011 Apr 28;342:d2238. doi: 10.1136/bmj.d2238.
10
Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients.CD4 计数低与 HIV 感染患者脆性骨折的风险增加相关。
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):205-10. doi: 10.1097/QAI.0b013e31821ecf4c.
Zotero 插件